Skip to content
10-Q

Quarterly Report

Sagimet Biosciences Inc. SGMT

0001104659-26-059006

← back to feed
Filed
May 12, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Diluted Q1 2026 · Mar 31, 2026 32.56M sh
Shares Diluted Q1 2026 · Mar 31, 2025 32.2M sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$8.61M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$14.54M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $36.63M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $35.02M
Stockholders Equity Q1 2026 · Mar 31, 2026 $102.46M
Stockholders Equity Q1 2026 · Dec 31, 2025 $111.38M
Stockholders Equity Q1 2026 · Mar 31, 2025 $138.99M
Stockholders Equity Q1 2026 · Dec 31, 2024 $155.81M
Current Liabilities Q1 2026 · Mar 31, 2026 $5.3M
Current Liabilities Q1 2026 · Dec 31, 2025 $5.1M
Current Assets Q1 2026 · Mar 31, 2026 $107.72M
Current Assets Q1 2026 · Dec 31, 2025 $116.4M
Total Assets Q1 2026 · Mar 31, 2026 $107.76M
Total Assets Q1 2026 · Dec 31, 2025 $116.48M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.33
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.56
Eps Basic Q1 2026 · Mar 31, 2026 −$0.33
Eps Basic Q1 2026 · Mar 31, 2025 −$0.56
Sga Expense Q1 2026 · Mar 31, 2026 $4.72M
Sga Expense Q1 2026 · Mar 31, 2025 $4.52M
Rd Expense Q1 2026 · Mar 31, 2026 $7M
Rd Expense Q1 2026 · Mar 31, 2025 $15.34M
Net Income Q1 2026 · Mar 31, 2026 −$10.65M
Net Income Q1 2026 · Mar 31, 2025 −$18.18M
Operating Income Q1 2026 · Mar 31, 2026 −$11.71M
Operating Income Q1 2026 · Mar 31, 2025 −$19.87M